Segment Information (Tables)

9 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Summary of Segment Information

The following table summarizes segment information for the three and nine month periods ended September 30, 2018 and 2017, respectively (in thousands).    

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017 (as adjusted)			2018		2017 (as adjusted)
Net revenues:
Clinical Services	$	59,449		$	51,187		$	175,960	$	159,642
Pharma Services	9,647			7,950			24,306		19,188
Total Revenue	$	69,096		$	59,137		$	200,266	$	178,830
Cost of revenue:
Clinical Services	$	31,509		$	30,150		$	94,586	$	91,854
Pharma Services	5,266			4,092			15,525		11,780
Total Cost of Revenue	$	36,775		$	34,242		$	110,111	$	103,634
Gross Profit:
Clinical Services	$	27,940		$	21,037		$	81,374	$	67,788
Pharma Services	4,381			3,858			8,781		7,408
Total Gross Profit	$	32,321		$	24,895		$	90,155	$	75,196
Operating expenses:
General and administrative	$	21,055		$	18,268		$	59,106	$	53,717
Research and development	446			1,270			2,475		3,080
Sales and marketing	6,900			6,363			21,355		18,142
Loss on sale of Path Logic	—			1,058			—		1,058
Total operating expenses	28,401			26,959			82,936		75,997
Income (Loss) from Operations	3,920			(2,064		)	7,219		(801		)
Interest expense, net	1,873			1,398			4,766		4,173
Other (income) expense	(30		)	—			31		—
Income (loss) before taxes	2,077			(3,462		)	2,422		(4,974		)
Income tax (benefit) expense	54			802			135		(30		)
Net Income (Loss)	$	2,023		$	(4,264	)	$	2,287	$	(4,944	)